Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer

Maximilian J Mair; Manfred Mitterer; Pia Gattinger; Julia M Berger; Rudolf Valenta; Dominic Fong; Matthias Preusser

doi:10.1001/jamaoncol.2022.4226

Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer

JAMA Oncol. 2022 Nov 1;8(11):1694-1696. doi: 10.1001/jamaoncol.2022.4226.

Authors

Maximilian J Mair¹, Manfred Mitterer², Pia Gattinger³, Julia M Berger¹, Rudolf Valenta³, Dominic Fong², Matthias Preusser¹

Affiliations

¹ Division of Oncology and Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
² Hemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
³ Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

No abstract available

Plain language summary

This cohort study assesses the capacity of passive immunization and tixagevimab and cilgavimab to inhibit interaction between receptor-binding domains and angiotensin-converting enzyme 2 in patients with hemato-oncologic diseases.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19* / prevention & control
Humans
Neoplasms* / drug therapy
SARS-CoV-2
Vaccination

Substances

cilgavimab
tixagevimab